



Figure 2: Correction of the Th17/Treg ratio is linked to the clinical response. **A, C:** Percentages of Treg, Th1 and Th17 cells (A) and Th17/Treg ratio (C) from RA patients before and after TCZ treatment (n=9). **B:** DAS28 before and after TCZ treatment in RA patients (n=9). **D:** Evolution of the DAS28 and the percentages of Treg and Th17 cells during the treatment of a RA patient with TCZ. Wilcoxon signed rank test was used. NS: not statistically significant. Error bars are the IQ range.